{
    "nctId": "NCT00509587",
    "briefTitle": "Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer",
    "officialTitle": "A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 21,
    "primaryOutcomeMeasure": "Number of Participants With Partial and Complete Response.",
    "eligibilityCriteria": "Criteria:\n\n* No prior bevacizumab\n* Histologically or cytologically confirmed invasive breast carcinoma (recurrent or metastatic disease)\n* Measurable disease, defined as \\>= 1 unidimensionally measurable lesion \\>= 20 mm by conventional techniques or \\>= 10 mm by spiral CT scan\n* Patients who may still benefit from hormonal therapy are ineligible (patients with hormone receptor-positive breast cancer should have received appropriate sequential hormonal therapy for metastatic disease until disease progression)\n* Patients with HER-2 positive disease who have not yet received trastuzumab (Herceptin\u00ae) to maximal benefit are ineligible (patients with disease progression during trastuzumab therapy are eligible)\n* No known brain metastases\n* ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%\n* Life expectancy \\> 12 weeks\n* Absolute neutrophil count \\>= 1,500/mm\u00b3\n* Platelets \\>=100,000/mm\u00b3\n* Total bilirubin normal (exception made for patients with known Gilbert's disease)\n* AST/ALT =\\< 2.5 times upper limit of normal (ULN)\n* No proteinuria \\> +1 on two consecutive dipsticks taken \\>= 1 week apart\n* PT/INR/PTT =\\< 1.2 times ULN\n* No allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other study agents\n* No QTc prolongation (defined as a QTc interval \\>= 500 msecs) or other significant ECG abnormalities\n* No condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or active peptic ulcer disease) that would impair ability to swallow and retain study drug\n* No poorly controlled hypertension (systolic blood pressure \\[BP\\] \\>= 140 mm Hg or diastolic BP \\>= 90 mm Hg) Initiation or adjustment of BP medication is allowed prior to study entry provided that the average of 3 BP readings prior to study entry is \\< 140/90 mm Hg\n* No serious or non-healing wound, ulcer, or bone fracture\n* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 4 weeks\n* No cerebrovascular accident within the last 6 months\n* No myocardial infarction, cardiac arrhythmia, hospital admission for unstable angina within the last 12 weeks\n* No venous thrombosis within the last 12 weeks\n* No NYHA class III-IV heart failure Patients with a history of class II heart failure may be considered eligible provided they are asymptomatic on treatment\n* No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would preclude study compliance\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgery\n* No cardiac angioplasty or stenting within the last 12 weeks\n* No more than 1 prior chemotherapy regimen for recurrent disease\n* No prior surgical procedures affecting absorption\n* No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:\n\nTherapeutic warfarin Low molecular weight heparin or prophylactic low-dose warfarin are allowed\n\n* No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:\n\n  * Erectile dysfunction agents: sildenafil, tadalafil, or vardenafil\n  * Antiarrhythmics: bepridil, flecainide, lidocaine, mexilitine, amiodarone, or quinidine\n  * Immune modulators: cyclosporine, tacrolimus, or sirolimus\n  * Miscellaneous: theophylline, quetiapine, or risperidone\n* No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:\n\n  * Oral hypoglycemics: glipizide, glyburide, or tolbutamide\n  * Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, or methylergonovine\n  * Neuroleptics: pimozide\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent investigational agents\n* No other concurrent anticancer therapy\n* WBC \\>= 3,000/mm\u00b3\n* No more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic disease\n* Creatinine normal OR creatinine clearance \\>= 60 mL/min\n* At least 3 months since prior trastuzumab",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}